Cibus (NASDAQ:CBUS) Raised to “Hold” at Wall Street Zen

Cibus (NASDAQ:CBUS) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings lowered Cibus from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Cibus currently has an average rating of “Hold” and an average price target of $9.00.

Cibus Stock Performance

Shares of NASDAQ CBUS opened at $1.70 on Friday. Cibus has a 1-year low of $1.09 and a 1-year high of $4.19. The company has a 50-day moving average of $1.50 and a two-hundred day moving average of $1.97. The company has a market cap of $129.76 million, a PE ratio of -0.86 and a beta of 1.65.

Cibus (NASDAQ:CBUS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.06). Cibus had a negative net margin of 2,366.33% and a negative return on equity of 200.87%. The company had revenue of $1.68 million for the quarter, compared to the consensus estimate of $1.61 million. As a group, equities research analysts forecast that Cibus will post -1.05 earnings per share for the current year.

Institutional Trading of Cibus

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Weiss Asset Management LP bought a new position in Cibus during the 1st quarter worth approximately $1,758,000. Prescott Group Capital Management L.L.C. acquired a new position in Cibus during the fourth quarter valued at approximately $345,000. Jane Street Group LLC acquired a new position in Cibus during the second quarter valued at approximately $207,000. Certior Financial Group LLC increased its stake in Cibus by 46.7% in the fourth quarter. Certior Financial Group LLC now owns 271,164 shares of the company’s stock valued at $472,000 after purchasing an additional 86,378 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new stake in Cibus in the fourth quarter valued at approximately $145,000. 33.81% of the stock is owned by institutional investors.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.